Amgen Inc. BDR (AMGN34) – cijena dionice i vijesti

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia

Amgen Inc. BDR – informacije

Glavni izvršni direktorRobert A. Bradway

Zaposlenici31,5 tis.

Osnovano1980

SjedišteThousand Oaks, Kalifornija, Sjedinjene Američke Države

Sektor-

Web-lokacijaamgen.com

Sve vrijednosti su u valuti USD	ruj 2025.	pro 2025.	ožu 2026.	lip 2026.
Prihod	9,56 mlr.	9,87 mlr.	8,62 mlr.	10,05 mlr.
Trošak prodane robe	2,74 mlr.	2,68 mlr.	2,50 mlr.	2,75 mlr.
Trošak prihoda	2,74 mlr.	2,68 mlr.	2,50 mlr.	2,75 mlr.
Izdaci za istraživanje i razvoj	1,90 mlr.	2,14 mlr.	1,72 mlr.	1,87 mlr.
Ukupni izdaci za istraživanje i razvoj	-	-	-	-
Izdaci za prodaju, opći i administrativni izdaci	1,72 mlr.	1,95 mlr.	1,60 mlr.	1,74 mlr.
Poslovni rashod	3,55 mlr.	4,18 mlr.	3,21 mlr.	3,73 mlr.
Ukupni poslovni rashodi	6,29 mlr.	6,85 mlr.	5,70 mlr.	6,48 mlr.
Poslovni prihod	3,26 mlr.	3,01 mlr.	2,91 mlr.	3,57 mlr.
Ostali neposlovni prihod	181,00 mil.	143,00 mil.	192,00 mil.	145,00 mil.
Zarada prije poreza uključujući neuobičajene stavke	3,92 mlr.	1,51 mlr.	2,08 mlr.	2,77 mlr.
Zarada prije poreza isključujući neuobičajene stavke	2,72 mlr.	2,51 mlr.	2,37 mlr.	3,06 mlr.
Izdaci za porez na dohodak	705,00 mil.	181,00 mil.	265,00 mil.	393,00 mil.
Efektivna porezna stopa	17,98 %	11,96 %	12,72 %	14,20 %
Ostali poslovni rashodi	−71,00 mil.	82,00 mil.	−113,00 mil.	116,00 mil.
Neto dohodak	3,22 mlr.	1,33 mlr.	1,82 mlr.	2,38 mlr.
Neto profitna marža	33,65 %	13,51 %	21,11 %	23,62 %
Zarada po dionici	5,64	5,29	5,15	6,29
Prihod od kamata i ulaganja	-	408,00 mil.	-	-
Izdaci za kamate	−685,00 mil.	−1,06 mlr.	−657,00 mil.	−673,00 mil.
Neto izdaci za kamate	−685,00 mil.	−653,00 mil.	−657,00 mil.	−673,00 mil.
Troškovi amortizacije i otpisa	-	-	-	-
Dobit prije kamata, poreza i amortizacije	4,57 mlr.	4,02 mlr.	4,03 mlr.	4,69 mlr.
Dobit ili gubitak od prodaje imovine	-	-	-	-

Pitajte bilo što